The firm increased its portfolio allocation in NEO by 11.85% over the last quarter ... the author and do not necessarily reflect those of Nasdaq, Inc. Fintel is a leading provider of financial ...

Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) fell short of the market’s revenue expectations in Q1 CY2025, ...

Q1 2025 Earnings Call Transcript April 29, 2025 NeoGenomics, Inc. misses on earnings expectations. Reported EPS is $-0.20352 ...

NeoGenomics (NEO) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to loss of $0.02 per share a year ago. These figures are ...

Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) fell 34.8% in the afternoon session after the ...

NeoGenomics shares dropped 34% on April 29 after missing its Q1 revenue estimates. Check out why I view the stock price ...

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on NeoGenomics (NASDAQ:NEO) in the last three months. The table below offers a condensed view ...

NeoGenomics (NASDAQ:NEO) stock gains as the company missed expectations with its Q1 2025 revenue, but raised full-year guidance, signalling growth ahead. Read more here.

Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) will be reporting earnings tomorrow morning. Here’s what ...

NeoGenomics Inc (NEO) reports an 8% revenue increase and strategic advancements, despite challenges in the non-clinical sector.

*Today’s High/Low is only updated during regular trading hours; and does not include trades occurring in pre-market or after-hours. Nasdaq Official Closing Price (NOCP)" is a process for ...

NeoGenomics, Inc.’s NEO share price has dipped by 19.36%, which has investors questioning if this is right time to buy.